6 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” Cepharanthine and berbamine may affect SK channels, influencing their therapeutic effects.
June 2023 in “International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science” New information shows Valproate may protect the brain and reduce breathing failure risk but can cause liver damage and other side effects, with genetics affecting dosage needs.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
18 citations
,
April 2011 in “Neuropharmacology” 11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.
9 citations
,
February 1996 in “Lancet” Some tuberculosis drugs may cause hair loss, but hair might regrow after treatment or changing the drugs.
90 citations
,
January 1989 in “PubMed” 8 citations
,
October 2002 in “Journal Of Clinical Periodontology” Levamisole and finasteride can reduce DHT production, potentially preventing phenytoin-induced gum overgrowth.
1 citations
,
May 2007 in “Emergency medicine news” Dr. Marina Kovalevsky and her daughter were hospitalized for suspected politically motivated thallium poisoning in Moscow.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
November 2022 in “Indian Journal of Dermatology/Indian journal of dermatology” Valproic acid can cause dark lines on nails.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
2 citations
,
November 2011 in “Current psychiatry” 70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
19 citations
,
January 1993 in “Dermatologic Clinics” 1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
5 citations
,
September 2015 in “Medical hypotheses” Topical sulfonylurea may reduce excessive hair growth caused by certain medications.
29 citations
,
March 1987 in “Therapeutic Drug Monitoring” Combining sodium valproate with other epilepsy drugs increases ammonia levels and side effects.
9 citations
,
April 1970 in “Biochemical pharmacology” Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.
12 citations
,
November 2024 in “International Journal of Molecular Sciences” Hydroxytyrosol helps reduce liver injury by blocking certain inflammation pathways.
1 citations
,
February 2025 in “South Asian Research Journal of Pharmaceutical Sciences” Eclipta alba flavonoids may help treat diabetes by effectively inhibiting Aldose reductase.
15 citations
,
May 2003 in “American Journal of Kidney Diseases” A hemodialysis patient's hair loss was caused by the drug tinzaparin but stopped after switching to a different drug.
31 citations
,
September 2014 in “International Journal of Dermatology” Anthralin is effective for psoriasis and alopecia with minimal systemic side effects but can irritate the skin.
2 citations
,
March 2019 in “Experimental Techniques in Urology & Nephrology” Heptaminol may cause hair lightening in hemodialysis patients.
88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
January 2025 in “Dusunen Adam The Journal of Psychiatry and Neurological Sciences”
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
1 citations
,
March 2022 in “British Journal of Clinical Pharmacology” 5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.